South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
https://www.pharmalive.com/wp-content/uploads/2020/08/Freenome-Raises-270-Million-to-Advance-Colorectal-Cancer-Liquid-Biopsy-BioSpace-8-26-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-08-26 11:47:472020-08-26 15:10:28Freenome Raises $270 Million to Advance Colorectal Cancer Liquid Biopsy